On July 7, 2025, Cogent Biosciences, Inc. reported positive results from its SUMMIT clinical trial for bezuclastinib in treating non-advanced systemic mastocytosis, achieving significant improvements in patient symptoms and planning to submit a new drug application to the FDA by the end of 2025. The trial showed a 24.3 point reduction in total symptom score for bezuclastinib patients compared to 15.4 points for the placebo, with a statistically significant p-value of 0.0002.